Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q1 2026 Earnings Presentation
8 slides from Sanuwave Health's earnings presentation, May 13, 2026
Slide 1: Q1 2026
(6) SANUWAVE Wound Care Technologies Q1 2026 May 13, 2026
Slide 2: Live Presentation and Participant Dial-in Information
Live Presentation Wednesday, May 13, 2026, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-833-316-1983 Toll/International: 1-785-838-9310 Conference ID: SANUWAVE OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1762392&tp_key=537d73
Slide 3: Forward Looking Statements and Non-GAAP Financial Measures
3 Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectati
Slide 4: Financials Q1 2026
4 Financials Q1 2026 Continued revenue growth while investing in commercial and operational expansion. (in millions) Q1 2026 Q1 2025 YoY Revenue $9.6 $9.3 + 3% Gross Profit $7.4 $7.4 0% Gross Margin % 77.3% 79.0% -170 bp Operating Expense $8.6 $6.8 +33% Revenue Gross Profit Operating (Loss) Income O
Slide 5: Improved Operational Results
5 Improved Operational Results See Non-GAAP Financial Measures disclosure included on slide 3 1 Depreciation and amortization excludes amortization of right-of-use (ROU) leases. Prior period amounts have been retroactively revised to conform to this presentation. This change had no effect on previou
Slide 6: UltraMIST Systems & Consumables Sales
6 UltraMIST Systems & Consumables Sales Change in sales of UltraMIST Systems and Applicators year on year. $8.0 *Please note: In Q4 2025, we transitioned to tracking Q1 2026: “active systems”, which are defined as those owned by customers who have ordered consumable applicators $7.0 + 15% yoy within
Slide 7: Q2 and FY 2026 Revenue Guidance
7 Q2 and FY 2026 Revenue Guidance Q2 2026 FY 2026 REVENUE TARGET REVENUE TARGET $11.1-11.6 Million $51.0-55.0 million (+10-15%) (+16-25%) vs vs Q2 2025 REVENUE FY 2025 REVENUE of $10.1 million of $44.1 million
Slide 8: Summary
8 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for patients, payors, and providers. SANUWAVE is in a prime position to benefit: ▪ Approved product protected by strong IP ▪ Strong existing reimbursement with room to impro